Investing.com -- Daxor Corporation (NASDAQ:DXR)股价在该公司获得其新一代血容量分析系统的FDA 510(k)许可后飙升40%。这款快速、紧凑、手持式设备有望彻底改变临床环境中的液体管理方式。 新获批的Daxor BVA™设备能够根据患者特定标准量化患者的血容量,为多种医疗状况下的精确液体管理提供关键数据。该系统处理结果的速度比其前代产品快三倍,同时在...
Source LinkInvesting.com -- Daxor Corporation (NASDAQ:DXR)股价在该公司获得其新一代血容量分析系统的FDA 510(k)许可后飙升40%。这款快速、紧凑、手持式设备有望彻底改变临床环境中的液体管理方式。 新获批的Daxor BVA™设备能够根据患者特定标准量化患者的血容量,为多种医疗状况下的精确液体管理提供关键数据。该系统处理结果的速度比其前代产品快三倍,同时在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.